Personalized Vaccination in Fusion+ Sarcoma Patients (PerVision)

Last updated: December 6, 2024
Sponsor: University Hospital Tuebingen
Overall Status: Active - Recruiting

Phase

1/2

Condition

Ewing's Family Tumors

Rhabdomyosarcoma

Sarcoma (Pediatric)

Treatment

Peptide vaccine IPX

Clinical Study ID

NCT06094101
2022-002793-91
  • Ages 2-40
  • All Genders

Study Summary

The PerVision trial utilizes an approach of a patient-individual cancer vaccine with sarcoma-specific peptides in metastasized fusion-driven sarcoma patients determined by next generation whole exome sequencing of tumor and normal tissue as well as RNA sequencing of the tumor.

This approach is applicable to all patients independent of the expression of distinct tumor associated antigens, and independent of their human leukocyte antigen-typing (HLA-typing). The results of this study can directly be translated to other tumor entities.

It is an interventional, multicenter, open-label, phase I/II feasibility and early proof of concept study evaluating a personalized peptide vaccine.

Primary objective is to evaluate safety and success of treatment, the latter be defined as vaccination-induced T-cell response without unacceptable toxicity.

Eligibility Criteria

Inclusion

Inclusion Criteria, definition of partial remission plus (PRplus)

  • Screening Stage 1:

  • Confirmed metastatic fusion-driven rhabdomyosarcoma, Ewing- and synovialsarcoma in first or second complete remission (CR) or partial response (PR)after local therapy and intensive standard chemotherapy protocols.

  • Whole exome sequencing and RNA sequencing data of the gene fusion (fusion-breakpoint RNA sequence) must be available by registration to theINFORM (Individualized therapy for relapsed malignancies in childhood), MASTER (Register study Molecularly Aided Stratification for Tumor Eradication) orHEROES-AYA networks (Heterogeneity, evolution and resistance of fusion-drivensarcomas in AYA) or similar evaluation.

  • Screening stage 2:

  • Design and production of the patient-individual vaccine cocktail was successful

  • Patients have reached a complete or stable partial remission (CR or PR) the endof adjuvant and/or maintenance cytotoxic treatment. Cytotoxic treatment as perstandard or trial recommendations has been completed. Definition of PRplus:Partial remission(plus) implicates that all remaining tumor residua includingall metastases have received local therapy by this time point: Either surgicalremoval or local irradiation. The assessment of which therapy modality and, inthe case of irradiation, which radiation dose is selected, lies with thetreating physician. Whether PRplus is achieved will be decided finally by theinvestigator after review of the patient records.

Exclusion

Exclusion Criteria:

  • Ejection fraction < 25%

  • Creatinine-clearance < 40ml/min

  • Bilirubin > 4mg/dl

  • Alanine aminotransferase (ALT) > 400 units (U)/l and/or aspartate aminotransferase (AST) > 400 U/l

  • Severe infection (Human immunodeficiency virus (HIV): positive for the presence ofhuman immunodeficiency virus-1 or human immunodeficiency virus-2 (positiveantigen/antibody or nucleic acid tests [NAT]) and CD4-positive cells < 500/μl.Hepatitis B virus: positive for the presence of hepatitis B virus (positive forhepatitis B core antibody [HBcAb] or positive hepatitis B surface antigen [HBsAg])and hepatitis B NAT test > 2000 IU/ml). Hepatitis C virus: positive for heavy chainonly antibody [HCAb] or for nucleic acid amplification testing (NAT). Otherinfections that, in the opinion of the investigator, do not allow a participation inthe study.)

  • Subjects with a known hypersensitivity / allergy to any component of the studydrugs.

  • Subjects who have received a live, attenuated vaccine within 28 days prior to theadministration of the study drug (only stage 2).

  • Subjects with a prior haematopoietic stem cell transplantation / prior organtransplantation.

  • Patients suffering from other malignancies (with the exception of those with anegligible risk of metastasis or death and treated with curative outcome) within 5years prior to study start.

  • Current or anticipated need for any of the following medications interfering with Tcell function from 14 days before 1st vaccination until 28 days after 1stvaccination: Immunosuppressive agents, which influence functionality and activity ofT cells, such as steroids (more than 0,5 mg/kg body weight prednisolone-equivalent),calcineurin-inhibitors, mofetil mycophenolate, sirolimus, everolimus, and cytotoxicmedication. Those drugs should be avoided until 28 days after third/finalvaccination but may be given after discussion with the principal investigator.Application of tyrosine kinase inhibitors is permitted during the trial (only stage 2).

  • Significant psychiatric disabilities that, in the judgment of the investigator, donot assure reliable participation in the present study.

  • Uncontrolled seizure disorders (occurrence of at least one generalized seizure inthe last 3 months) or severe peripheral neuropathy/leucoencephalopathy (> grade 2according to NCI CTCAE v5.0 neurotoxicity criteria).

  • Autoimmune disease (e.g. idiopathic thrombocytopenic purpura, autoimmune hemolyticanemia, autoimmune dermatitis) requiring immunosuppressive treatment

  • Pregnant females

  • Female subjects of childbearing potential (postmenarcheal, with an intact uterus andat least one ovary, and less than one year postmenopausal) not agreeing to useacceptable method(s) of contraception from 30 days prior to Screening stage 2 visitto 180 days after the last vaccination.

  • Male subjects of reproductive capacity not agreeing to use effective contraceptionfrom first vaccination of this study to 180 days after the last vaccination.

  • Not willing and/or not able to comply with treatment plan, scheduled visits,laboratory tests, contraceptive guidelines and other study procedures.

  • History of any illness or clinical condition that might confound the results of thestudy or pose an additional risk in administering study drug to the subject,according to the judgement of the investigator. This may include but is not limitedto: history of central nervous system or cardiovascular disease, history of relevantdrug allergies, history of psychiatric disorder, history or present of clinicallysignificant pathology.

  • Karnofsky performance status of < 70% for subjects ≥ 16 years of age, Lanskyperformance status of < 70% for subjects < 16 years of age

  • Participation or intended participation in another clinical phase I or II trial withan investigational drug or product within 28 days prior to enrollment (with theexception to participation of the "frontline and relapsed rhabdomyosarcoma study"( (FaR-RMS) after completion of the maintenance therapy (EudraCT-2018-000515-24)).Commonly used drugs as per standard or phase III-trials are permitted.

Study Design

Total Participants: 30
Treatment Group(s): 1
Primary Treatment: Peptide vaccine IPX
Phase: 1/2
Study Start date:
September 19, 2023
Estimated Completion Date:
September 30, 2027

Study Description

The PerVision trial utilizes an approach of a patient-individual cancer vaccine with sarcoma-specific peptides (one peptide derived from the sarcoma-specific fusion breakpoint, 'fusion-peptide', and a second peptide derived from neoantigens derived from patient-specific non-synonymous mutations with the highest prediction score, 'mutation-based neopeptide') in metastasized fusion-driven sarcoma patients determined by next generation whole exome sequencing of tumor and normal tissue as well as RNA sequencing of the tumor.

This approach is applicable to all patients independent of the expression of distinct tumor associated antigens, and independent of their human leukocyte antigen-typing (HLA-typing). The results of this study can directly be translated to other tumor entities.

It is an interventional, multicenter, open-label, phase I/II feasibility and early proof of concept study evaluating a personalized peptide vaccine and the toll like receptor (TLR) 1/2 ligand XS15 emulsified in Montanide ISA 51 VG in fusion driven sarcoma patients.

The principal questions are:

  1. To investigate, whether it is possible to induce a mutation-specific immune response in sarcoma patients and young adults after salvage chemotherapy

  2. To investigate possible side effects and toxicity of the treatment

  3. To gather indications if our approach has a beneficial effect on residual disease as well as event free survival (EFS) of the patients. EFS and overall survival (OS) data will be compared within this single arm study to non-vaccinated patients of a historic control cohort.

Patients will be recruited through the Society for Pediatric Oncology/Hematology (GPOH) networks Cooperative Soft Tissue Sarcoma Group (CWS) and Cooperative Ewing Sarcoma Group (CESS) and through the "Deutsches Konsortium für Translationale Krebsforschung" (DKTK) programs MASTER and INFORM as well as HEROES-AYA. For the screening phase, n=30 patients will be recruited, n=23 patients should be treated with at least one vaccine dose, with a drop-out rate we need n=21 patients for sufficient statistical power.

Primary objective is to evaluate the safety, toxicity and in vivo immunological effects of a patient-individualized peptide vaccination (IPX vaccine) in patients with primary or relapsed metastasized fusion-driven sarcoma (FDS, rhabdomyosarcoma, Ewing- and synovial sarcoma) with an age ≥ 2 to < 40 years in first or second complete remission or stable partial remission.

Primary endpoint is "success of treatment", defined as the patient showing a vaccination-induced T cell response without unacceptable toxicity until Follow-up visit (28 ± 7 days after last vaccination).

Connect with a study center

  • Pediatrics III, West German Cancer Centre, University Hospital

    Essen, 45147
    Germany

    Site Not Available

  • Universitätsklinikum, Klinik für Kinder- und Jugendmedizin

    Frankfurt am Main, 60590
    Germany

    Site Not Available

  • Zentrum für Kinder- und Jugendmedizin, Universitätsklinikum

    Freiburg, 79106
    Germany

    Site Not Available

  • University Children's Hostpital

    Tübingen, 72076
    Germany

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.